BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 12577249)

  • 1. Using technology to decrease xerostomia for head and neck cancer patients treated with radiation therapy.
    Amosson CM; Teh BS; Mai WY; Woo SY; Chiu JK; Donovan DT; Parke R; Carpenter LS; Lu HH; Grant WH; Butler EB
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):71-9. PubMed ID: 12577249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformal and intensity modulated irradiation of head and neck cancer: the potential for improved target irradiation, salivary gland function, and quality of life.
    Eisbruch A; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Anzai Y; Marsh LH; Martel MK; Ten Haken RK; Wolf GT; Ship JA
    Acta Otorhinolaryngol Belg; 1999; 53(3):271-5. PubMed ID: 10635407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
    Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
    Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.
    Blanco AI; Chao KS; El Naqa I; Franklin GE; Zakarian K; Vicic M; Deasy JO
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1055-69. PubMed ID: 15990009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
    Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer.
    Saarilahti K; Kouri M; Collan J; Kangasmäki A; Atula T; Joensuu H; Tenhunen M
    Radiother Oncol; 2006 Mar; 78(3):270-5. PubMed ID: 16564589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy.
    Strigari L; Benassi M; Arcangeli G; Bruzzaniti V; Giovinazzo G; Marucci L
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):269-76. PubMed ID: 20100642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity-modulated radiation therapy and xerostomia.
    Chambers MS; Weber RS; Garden AS
    J Calif Dent Assoc; 2006 Sep; 34(9):743-8. PubMed ID: 17022299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors.
    Wijers OB; Levendag PC; Braaksma MM; Boonzaaijer M; Visch LL; Schmitz PI
    Head Neck; 2002 Aug; 24(8):737-47. PubMed ID: 12203798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer.
    Bussels B; Maes A; Hermans R; Nuyts S; Weltens C; Van den Bogaert W
    Radiother Oncol; 2004 Aug; 72(2):119-27. PubMed ID: 15297131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of Cepharanthin to prevent radiation induced xerostomia in head and neck cancer].
    Imada H; Nomoto S; Ohguri T; Yahara K; Kato F; Morioka T; Korogi Y
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1041-5. PubMed ID: 15272582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing radiation induced xerostomia.
    Koukourakis MI; Danielidis V
    Cancer Treat Rev; 2005 Nov; 31(7):546-54. PubMed ID: 16257125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study.
    Burlage FR; Roesink JM; Kampinga HH; Coppes RP; Terhaard C; Langendijk JA; van Luijk P; Stokman MA; Vissink A
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):14-22. PubMed ID: 17869018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large cohort dose-volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy.
    Dijkema T; Terhaard CH; Roesink JM; Braam PM; van Gils CH; Moerland MA; Raaijmakers CP
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1101-9. PubMed ID: 18472355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma.
    Daly ME; Lieskovsky Y; Pawlicki T; Yau J; Pinto H; Kaplan M; Fee WE; Koong A; Goffinet DR; Xing L; Le QT
    Head Neck; 2007 Mar; 29(3):211-20. PubMed ID: 17111429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients.
    Scarantino C; LeVeque F; Swann RS; White R; Schulsinger A; Hodson DI; Meredith R; Foote R; Brachman D; Lee N
    J Support Oncol; 2006 May; 4(5):252-8. PubMed ID: 16724649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current radiotherapic procedures and preservation of salivary function in patients with head and neck cancer.
    Donato V; Bulzonetti N; Monaco A; Messineo D; Caiazzo R; Banelli E
    Acta Otorhinolaryngol Ital; 2004 Oct; 24(5):275-8. PubMed ID: 15871608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.